Investor Relations

OUR LEAD ONCOLOGY CANDIDATE, OFRA-VEC, IS CURRENTLY BEING EVALUATED IN OUR OVAL PHASE 3 REGISTRATION-ENABLING CLINICAL TRIAL IN OVARIAN CANCER. READOUT OF OVAL PFS CO-PRIMARY ENDPOINT IS EXPECTED IN THE SECOND HALF OF 2022. FOR ADDITIONAL INFORMATION AND CATALYSTS, SEE OUR CORPORATE PRESENTATION.

Press Releases

May 17, 2022
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Read More
May 10, 2022
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
Read More

Events & Presentations

May 23 - May 26, 2022
H.C. Wainwright Global Investment Conference
Read More
May 17, 2022 at 8:30 AM EDT
VBL Therapeutics Q1 2022 Financial Results
Read More

Corporate Presentation

May
May 20, 2022 1:50 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart